Sorry, you need to enable JavaScript to visit this website.
DeliverinG THE LATEST
GREENSTONE News Archive

Get up-to-date product and event news, including information on our generic products.

GREENSTONE LLC INTRODUCES PHENYTOIN TABLETS—Its Latest Generic Pharmaceutical Product

PEAPACK, N.J., December 2012 — Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Phenytoin Tablets, USP to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strength of 50mg.

Read more »

GREENSTONE LLC INTRODUCES SILDENAFIL TABLETS—Its Latest Generic Pharmaceutical Product

PEAPACK, N.J., November 2012 — Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Sildenafil Tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strength of 20mg.

Read more »

GREENSTONE LLC INTRODUCES DICLOFENAC SODIUM/MISOPROSTOL TABLETS—Its Latest Generic Pharmaceutical Product

PEAPACK, N.J., November 2012 — Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Diclofenac Sodium/Misoprostol tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 50mg and 75mg.

Read more »

GREENSTONE LLC INTRODUCES PHENYTOIN ORAL SUSPENSION, USP—Its Latest Generic Pharmaceutical Product

PEAPACK, N.J., October 2012 — Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Phenytoin Oral Suspension, USP to its ever-expanding generic pharmaceutical product line.

Read more »

GREENSTONE LLC INTRODUCES TRIFLURIDINE OPHTHALMIC SOLUTION—Its Latest Generic Pharmaceutical Product

PEAPACK, N.J., September 2012 — Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Trifluridine Ophthalmic Solution to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strength of 7.5 mL.

Read more »

Greenstone LLC Introduces MONTELUKAST Sodium Tablets and Chewable Tablets—Its Latest Generic Pharmaceutical Product

PEAPACK, N.J., August 2012 — Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Montelukast Sodium Tablets and Chewable Tablets to its ever-expanding generic pharmaceutical product line. The tablets are offered in dosage strengths of 10 mg and the chewable tablets are offered in dosage strengths of 4 mg and 5 mg.

Read more »

Greenstone LLC Announces Introduction of Olanzapine Tablets—Its Latest Generic Pharmaceutical Product

PEAPACK, N.J., May 2012 — Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Olanzapine Tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg tablets.

Read more »

Greenstone LLC Announces Introduction of Ziprasidone HCl Capsules—Its Latest Generic Pharmaceutical Product

PEAPACK, N.J., April 2012 — Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Ziprasidone HCl Capsules to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 20 mg, 40 mg, 60 mg, and 80 mg capsules.

Read more »

Greenstone LLC Introduces 12 Generic Products to Date in 2011

Peapack, NJ; October 2011 — Through just the first nine months of 2011, Greenstone LLC, the generic pharmaceutical subsidiary of Pfizer Inc., has expanded its line of product offerings by introducing 12 additional generics, bringing the company’s current portfolio to more than 80 generic medicines.

Among this group of 12 new products are the following:

Read more »

Greenstone LLC Announces Introduction of Exemestane Tablets—Its Latest Generic Pharmaceutical Product

PEAPACK, N.J., May, 2011 — Greenstone LLC, the generic pharmaceutical subsidiary of Pfizer Inc., is pleased to announce the introduction of EXEMESTANE tablets to its ever-expanding generic pharmaceutical product line.

EXEMESTANE is the authorized generic of, and thereby fully substitutable for, Aromasin®. This new generic product from Greenstone is being offered in 25 mg tablets, available in bottles of 30 tablets.

Read more »

Greenstone LLC Announces Introduction of Latanoprost Ophthalmic Solution—Its Latest Generic Pharmaceutical Product

PEAPACK, N.J., May, 2011 — Greenstone LLC, the generic pharmaceutical subsidiary of Pfizer Inc., is pleased to announce the introduction of LATANOPROST to its ever-expanding generic pharmaceutical product line.

LATANOPROST is the authorized generic of, and thereby fully substitutable for, Xalatan®. This new generic product from Greenstone is being offered in 125 mcg/2.5 mL Solution, available in single count and three count cartons.

Read more »

Notification of Product Theft

May 18, 2011 — Pfizer and its Greenstone subsidiary are working with the U.S. Food and Drug Administration, Office of Criminal Investigations (OCI), and other law enforcement officials to recover several different Greenstone products that were stolen on May 14, 2011 while being delivered from Pfizer’s Memphis facility to a customer in the Northeast. The products stolen are listed below. In every instance these products represent a small portion of each product lot.

Read more »

Greenstone Announces Voluntary Nationwide Recall of Citalopram and Finasteride Due to Possible Mislabeling

PEAPACK, N.J., March 26, 2011 — Greenstone LLC announced today that it is voluntarily conducting a recall, to the patient level, of medicines with lot number FI0510058-A on the label. This includes Citalopram 10mg Tablets [100-count bottle] and Finasteride 5mg Tablets [90-count bottle], both distributed in the U.S. market. The recall is due to the possibility that incorrect labels have been placed on the bottles by a third-party manufacturer. This is the only lot number being recalled and no other lots or markets are believed to be impacted.

Read more »

Greenstone Selected as Eisai Partner to Launch Authorized Generic of Aricept® (Donepezil HCl) Tablets

- Agreement rapidly expands Greenstone's line of Authorized Generics

Read more »